Tech Company Financing Transactions
Neuron23 Funding Round
Neuron23, operating out of San Francisco, received $113.5 million in investment from Redmile Group, Acorn Bioventures and Cowen Capital Partners.
Transaction Overview
Company Name
Announced On
12/17/2020
Transaction Type
Venture Equity
Amount
$113,500,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of its pipeline and expand its artificial intelligence (AI)-enabled drug discovery and biomarker platforms for identifying therapeutics for devastating neurodegenerative diseases including Parkinson's disease, neuroinflammatory diseases such as multiple sclerosis, and systemic autoimmune and inflammatory diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, USA, and Munich, Germany. Working with leading geneticists and valued partners like Origenis, Neuron23 leverages genetic breakthroughs and artificial intelligence technology to discover promising approaches and develop new drugs more efficiently than ever before.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/17/2020: Neo Financial venture capital transaction
Next: 12/17/2020: CHAOSSEARCH venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC transactions on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs